RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @CDNCancerTrials: Great news for #breastcancer patients around the world! Many women with early-stage forms of the disease can forego ch…
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy for HR–positive, HER2-negative, axillary node–negative breast cancer with a mid-range score on Oncotype DX https://t.co/lPiRKzLO48
RT @tdcil: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/FPbvgPBAHQ
Changing paradigms in management of breast cancer. No longer adjuvant chemotherapy needed in localized hormone receptor cancers, particularly in women above 50. Also amazing use of gene expression assays! https://t.co/cuYqGnmdxB
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @WaywardCell: Remarkable figure from the NEJM paper showing that many women with early breast cancer can be spared adjuvant chemotherapy…
rethinking breast cancer chemotherapy #ctisus... https://t.co/kVNWPnNaAa
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
A study published Sunday finds that many women with early-stage invasive breast cancer could safely forgo chemotherapy, if they score in the midrange or lower for risk that their cancer will recur, as measured by a commonly used genomic test: https://t.co/
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @ESteyerberg: A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @JJRiosBlanco: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/jdG5TwGx5P
This study found that "a significant number of women with early-stage breast cancer may not require chemotherapy—which could potentially be a huge deal for tens of thousands of patients at the edges of the disease" https://t.co/l8x98z9ScA? YAY science! via
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Study result of TAILORx was published in @NEJM, indicating that chemo therapy could be replaced by adjuvant endocrine therapy in 70% of early-stage breast cancer which chemo is ineffective. #ASCO @ASCO Via @GenomicHealth Link: https://t.co/yMKcREiNq3, http
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/jdG5TwGx5P
RT @roentgen66: Los resultados del estudio TAILORx presentados en #ASCO18 permitirán evitar quimioterapia en grupo de riesgo intermedio htt…
Study shows noninferiority of endocrine alone vs chemoendocrine therapy for disease–free survival in breast cancer with mid-range gene expression score! #ASCO18 https://t.co/cNhZ411YYC
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @roentgen66: Los resultados del estudio TAILORx presentados en #ASCO18 permitirán evitar quimioterapia en grupo de riesgo intermedio htt…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @veleveljkovic: According to study published in the leading medical journal, 70 % of patients who are diagnosed with the most common for…
Results of TAILORx study will be practice changing! Patients with ER positive, Her2 negative, node negative and a mid-range 21 gene assay reccurence score, may safely avoid chemotherapy. There is some benefit of chemotherapy however in women <50 yrs #br
RT @CarinneAnderson: #TAILORx results are in! #bcsm #ASCO18 @NEJM https://t.co/mlhURJLnd3
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @roentgen66: Los resultados del estudio TAILORx presentados en #ASCO18 permitirán evitar quimioterapia en grupo de riesgo intermedio htt…
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @ESteyerberg: A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At…
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @whyes: 大部分的早期的乳腺癌病人根治性手术之后接受内分泌治疗就可以了,不必接受化疗。这可能是 #ASCO18 最重要的一项研究,看到时间线上纽约时报和CNN也报道了这项研究结果。 https://t.co/lukWHrDjAw
RT @sanwolfy: 强转。 https://t.co/PWubjDomS2
RT @DrLoveResearch: About 70% of women diagnosed w/ the early stages of one of the most common forms of breast cancer might not need chemot…
Great news that so many women can confidently avoid chemotherapy for their breast cancer https://t.co/ojsQUrOl16
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Important finding: for younger women with HER2–negative #breastcancer, adjuvant endocrine therapy was as effective as chemotherapy. Full article here: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/ii4A9Pzo
RT @roentgen66: Los resultados del estudio TAILORx presentados en #ASCO18 permitirán evitar quimioterapia en grupo de riesgo intermedio htt…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Good news for #BreastCancer patients: 60,000 per year can safely skip chemo, study suggests https://t.co/J2NVVrxJWy
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Thanks to genomic testing, 70% of Breast Cancer Patients Can Skip Chemotherapy https://t.co/PUdkQFmuVU
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
NEJM article here: https://t.co/m34Y2dSzNH
RT @michellelewing: #confirmation for me, #breastcancersurvivor of a good decision 💗 #oncotype 14 #NationalCancerSurvivorsDay https://t.co/…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
#confirmation for me, #breastcancersurvivor of a good decision 💗 #oncotype 14 #NationalCancerSurvivorsDay https://t.co/N12WoWdmGB
RT @HenrychihangFu1: A landmark study. Strength of the study: ~ 10,000 pts with median follow up of 90 mons. Weakness of clinical trial: it…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
Great news in the field of #breastcancer research! #TranslationalScience #collaboration https://t.co/gYIl0bTvlF
RT @CDNCancerTrials: Great news for #breastcancer patients around the world! Many women with early-stage forms of the disease can forego ch…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
About 70% of women diagnosed w/ the early stages of one of the most common forms of breast cancer might not need chemotherapy as part of treatment, according to results of study presented at the American Society of Clinical Oncology. https://t.co/qRwiVtqul
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCancer, including all women >50yrs old w/ Breast Recurrence Scores® of 0 - 25 and all women aged 50 or younger w/ scores of 0 to 15 htt
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Top studies published in @NEJM this week during #ASCO18: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/209xij64cY Nephrectomy in Metastatic Renal-Cell Carcinoma https://t.co/XhXSZ4LoIM Visit https://t.co/g6psTR5pSl for more late-breaki
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
Absolutely the proudest moment in my professional career @GenomicHealth...I have had thousands of discussions with MD’s regarding the clinical value utility of @Oncotype_Breast assay. Grateful for the many woman who participated in this landmark trial. h
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @AJacomeMD: TAILORx was just published. Let’s pay attention to inclusion criteria: node+ patients and tumor > 5cm were not included. #Pr…
TailorX presented at #ASCO18 shows women with intermediate risk Oncotype scores may not need chemotherapy. @NEJM just published the article. https://t.co/jCUm9YqPlH. #BTSM
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Was so pumped to read the #TAILORx data last night. I remember when we used to say "one day we'll know" and now it's here. Next step for #precisionmedicine: https://t.co/whVTNyGNBY